Attoquant Diagnostics

Executive Summary

Attoquant Diagnostics is a Vienna-based Austrian biotechnology company founded in 2014, specializing in high-quality LC-MS/MS based peptide quantification services with a primary focus on the Renin-Angiotensin-Aldosterone System (RAAS). The company offers proprietary diagnostic panels and enzyme activity assays to support research and clinical development in cardiovascular and renal diseases. By leveraging advanced mass spectrometry, Attoquant enables precise biochemical characterization of RAAS components, which is critical for understanding hypertension, heart failure, and chronic kidney disease. Their technology provides a competitive edge in accuracy and multiplexing capabilities compared to traditional immunoassays, positioning them as a key partner for pharmaceutical companies and academic researchers in the cardiovascular and renal therapeutic areas. Attoquant operates in a niche but growing market driven by the increasing prevalence of cardiorenal diseases and the need for precise biomarkers in drug development. While the company is privately held and has not disclosed funding rounds, its services are commercially available, and it has likely established collaborations with biopharma firms. The near-term outlook depends on expanding its test menu, securing regulatory certifications (e.g., CE marking or CLIA), and forming strategic partnerships. Given the specialized nature of its offerings and the trend toward precision medicine, Attoquant has opportunities for growth, though competition from larger diagnostics companies and alternative technologies may pose challenges.

Upcoming Catalysts (preview)

• Q2 2026CE Marking of RAAS Panel for Clinical Use70% success
• Q4 2026Strategic Partnership with a Major Pharmaceutical Company50% success
• Q1 2027Publication of Clinical Validation Data in a Peer-Reviewed Journal80% success